Metabolic history impacts mammary tumor epithelial hierarchy and early drug response in mice

Maria Theresa E Montales1, Stepan B Melnyk2,3, Shi J Liu4, Frank A Simmen1,5, Y Lucy Liu5,6 and Rosalia C M Simmen1,5

1Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
2Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
3Arkansas Children's Hospital Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
4Department of Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
5The Winthrop P Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
6Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Abstract

The emerging links between breast cancer and metabolic dysfunctions brought forth by the obesity pandemic predict a disproportionate early disease onset in successive generations. Moreover, sensitivity to chemotherapeutic agents may be influenced by the patient’s metabolic status that affects the disease outcome. Maternal metabolic stress as a determinant of drug response in progeny is not well defined. Here, we evaluated mammary tumor response to doxorubicin in female mouse mammary tumor virus–Wnt1 transgenic offspring exposed to a metabolically compromised environment imposed by maternal high-fat diet. Control progeny were from dams consuming diets with regular fat content. Maternal high-fat diet exposure increased tumor incidence and reduced tumor latency but did not affect tumor volume response to doxorubicin, compared with control diet exposure. However, doxorubicin-treated tumors from high-fat-diet-exposed offspring demonstrated higher proliferation status (Ki-67), mammary stem cell-associated gene expression (Notch1, Aldh1) and basal stem cell-like (CD29hiCD24+) epithelial subpopulation frequencies, than tumors from control diet progeny. Notably, all epithelial subpopulations (CD29hiCD24+, CD29loCD24+, CD29hiCD24-Thy1+) in tumors from high-fat-diet-exposed offspring were refractory to doxorubicin. Further, sera from high-fat-diet-exposed offspring promoted sphere formation of mouse mammary tumor epithelial cells and of human MCF7 cells. Untargeted metabolomics analyses identified higher levels of kynurenine and 2-hydroxyglutarate in plasma of high-fat diet than control diet offspring. Kynurenine/doxorubicin co-treatment of MCF7 cells enhanced the ability to form mammosphere and decreased apoptosis, relative to doxorubicin-only-treated cells. Maternal metabolic dysfunctions during pregnancy and lactation may be targeted to reduce breast cancer risk and improve early drug response in progeny, and may inform clinical management of disease.
Introduction

Breast cancer is the most common malignancy of women worldwide, with a lifetime risk approximating 12% in the Western world (DeSantis et al. 2013). While disease initiation and progression result from genetic and epigenetic changes (Hanahan & Weinberg 2011), the heterogenous nature of breast cancer categorized by different clinical and molecular subtypes (Prat & Perou 2011) and manifested as subclonal heterogeneity within tumors (Martelotto et al. 2014) presents an enormous challenge for its clinical management. The increasing disease incidence in younger women coincident with the global obesity pandemic suggests that a disproportionate early disease onset is conceivable in successive generations, consistent with Barker's fetal origins of adult disease hypothesis (Barker 1996). Although support for precision medicine that considers the patient’s genetic make-up has gained substantial momentum (Narod 2015), it remains a highly expensive proposition and currently unattainable for the general population. Understanding the causes, prognosis and prediction of breast cancer heterogeneity can significantly affect breast cancer prevention and therapy (Brooks et al. 2015).

Metabolic stress in the early-life environment, imposed by maternal overnutrition and obesity, is a predisposing factor for increased risk of adult metabolic syndrome in human, primate and rodent offspring (Srinivasan et al. 2006, Dyer & Rosenfeld 2011). Moreover, increasing evidence supports a possible link between metabolic syndrome and breast cancer (Simmen & Simmen 2011, Hauner & Hauner 2014). A recent study from our group (Montales et al. 2014) provided a proof of this concept using the Wnt1 transgenic (Tg) mouse model of human breast cancer (Li et al. 2000). In this study, female offspring of dams consuming high-fat diet (HFD) that were weaned to a diet with regular fat content (control diet, CD), which continued through adulthood, exhibited higher mammary tumor incidence and shorter tumor latency than offspring of CD-fed dams. The metabolic stress status of HFD dams, manifested as elevated levels of serum glucose and oxidative stress biomarkers at the completion of lactation, was mimicked by pups at adulthood, which also exhibited dysregulated insulin signaling (Montales et al. 2014). Nevertheless, the duration, magnitude and significance of maternal metabolic stress in influencing offspring tumor outcomes remain unclear and, in population-based studies, are difficult to delineate, due to confounding environment and lifestyle risk factors between generations.

The success of currently available anthracycline- and taxane-based drugs in improving the outcome of early breast cancer remains limited to a small proportion of patients due to varying responses and toxicities caused by these drugs at high doses. To circumvent these limitations, potential genomic predictors of drug sensitivity are now being examined in patients with different tumor types. In one such study (Martin et al. 2011), resistance to doxorubicin was correlated with estrogen receptor-negative tumor status and with basal-like tumor subtype. Although potentially valuable in enhancing treatment options for breast cancer patients, these analyses did not address the etiology of tumor subtypes that may underlie drug response. In this study, we utilized the Wnt1 Tg mouse model and the maternal HFD paradigm to assess the effects of maternal metabolic history on chemotherapeutic sensitivity to doxorubicin in primary mammary tumors of offspring and to elucidate the underlying mechanism(s).

Materials and methods

Animals and diets

Animal studies were conducted in accordance with the protocols approved by the University of Arkansas for Medical Sciences Institutional Animal Care and Use Committee. Mice were housed in polycarbonate cages under the following conditions: 24°C, 40% humidity and a 12h light:12h darkness cycle. Food and water were provided ad libitum. Male MMTV–Wnt1 Tg mice (B6SJL-Tg(Wnt1)1Hev/J) and wild-type (WT) females of the same strain were obtained from Jackson Laboratories. To produce the offspring for this study, WT females were randomly assigned to one of the two American Institute of Nutrition-93G-based pelleted diets (Harlan, Indianapolis, IN, USA) beginning at weaning (postnatal day (PND) 21). The composition of the individual diets differed largely by fat content (control diet (CD)=17% vs high-fat diet (HFD)=45% total kcal from lard fat). HFD also had higher maltodextrin and sucrose content (the latter by 1.5-fold) compared with CD (Supplementary Table 1, see section on supplementary data given at the end of this article), thus closely recapitulating a typical ‘Western diet’ (Wilson et al. 2007). After 12 weeks on their assigned diets, females were bred with CD-fed Wnt1 Tg males. Plug-positive dams were continued on their respective diets throughout pregnancy and lactation (Fig. 1A). At weaning, offspring
from CD or HFD dams (designated hereafter CDO or HFDO) were genotyped for the presence or absence of Wnt1 transgene by PCR of genomic DNA from tail snips (Rahal et al. 2013a). Female pups of both genotypes were weaned to CD and used for the analyses described below. A total of 33 CDO and 23 HFDO Wnt1 Tg mice were monitored for spontaneous mammary tumor formation by weekly palpation beginning at 4 weeks and continued until 6 months of age (Fig. 1A). Random blood glucose levels were measured from tail vein blood by glucometer (One Touch; LifeScan, Milpitas, CA, USA) using glucose strips. Mice with no detectable tumors at age 6 months were killed.

Doxorubicin injection and tumor collection
To evaluate if early exposure to HFD alters response of offspring to the chemotherapeutic drug doxorubicin (Dox), tumor-bearing Wnt1 Tg females of both diet groups were twice administered Dox (Pfizer) at a dose of 8 mg/kg body weight by intraperitoneal injection (Fig. 2A). The first Dox treatment occurred 1 week after initial tumor detection, with the second injection administered 1 week after the first injection. Tumor size and left ventricular (LV) function were assessed via high-frequency ultrasound biomicroscopy (UBM) using a Vevo 2100 system (VisualSonics, Toronto, Canada) immediately before the first Dox administration and 1 week after the second Dox treatment at tissue harvest. Briefly, mice were anesthetized with 1.5% isoflurane (Thermo Fisher Scientific) and then quickly placed in dorsal recumbency on a temperature-controlled platform under 0.8–1% isoflurane anesthesia with four legs taped onto ECG electrodes. Throughout the experiment, the body temperature of mice was monitored with a rectal thermometer. Hair in chest and tumor areas was removed and a prewarmed ultrasound gel was applied to the cleaned area. UBM imaging was acquired using a high-frequency transducer (MS550D with 40 MHz), and data were analyzed with VisualSonics software. Imaging of tumor size was started from the long-axis view followed by the short-axis view to obtain the maximum sagittal and transactional diameter, respectively. The total volume of the tumor was assessed by three-dimensional imaging modality. The M-mode images from the left parasternal long-axis view with the 2-D B-mode image were used to measure LV function (Liu 2014). Repeated measures of LV function (4–6 cardiac cycles) were performed for each mouse.

Analyses of mammary tumors from Dox-treated mice
Excised tumors from Dox-treated CDO and HFDO were classified as Dox-sensitive or Dox-insensitive, based on...
changes in tumor volumes after Dox treatments (above). Dox-insensitive tumors (i.e., those whose volumes were increased or did not change with Dox administration) for each diet group were analyzed by quantitative real-time PCR (QPCR) for expression of tumor suppressor (Pten, Egr1), antiapoptotic (Bcl2), tumor inducer (Stat1, Il6) and stem cell marker (Notch1, Notch2, Aldh1) genes and by immunohistochemistry for PTEN, EGR1 and Ki-67 proteins. Tumor sections were prepared as described previously (Rahal et al. 2013a,b). Immunostaining with rabbit anti-human PTEN antibody (Cell Signaling Technology; 1:200 dilution), rabbit anti-EGR1 antibody (Cell Signaling Technology; 1:1000 dilution) and rabbit anti-Ki-67 antibody (Abcam; 1:100) followed the protocols described previously (Heard et al. 2014, Montales et al. 2014). Five randomly selected fields per tumor section per mouse were analyzed, and percent (％) immunostaining was calculated by counting the number of nuclear-immunostained cells over the total number of cells counted (×100) using Aperio ImageScope and Aperio-associated software (Vista, CA, USA). Procedures for RNA isolation, cDNA synthesis and primer design were as described previously (Montales et al. 2014). Real-time QPCR was performed on an ABI Prism 7000 Detection System (Applied Biosystems). Target messenger RNA expression was normalized to a factor that was derived from the geometric mean of expression for TATA-box-binding protein, β-actin and cyclophilin A, using GeNorm excel file software (Al-Dwairi et al. 2012). A total of 4 (immunostaining) and 4–6 (QPCR) Dox-insensitive tumors, each harvested from a different mouse within each diet group, were analyzed.

**In vitro assays of epithelial mammary tumor cells**

Tumors were isolated from CDO and HFDO (3 individual mice per diet group), 1 week after the initial
tumor detection. The isolation of epithelial mammary
tumor cells (designated T-MEC) was described
previously (Montales et al. 2012). Cells were plated
in the appropriate culture medium for each assay
and treated or not treated with Dox (100 nM) with or
without added sera (5% final concentration). Sera were
harvested from PND85 WT CDO or PND85 WT HFDO
(n = 6 mice per diet group) and pooled in equal volumes
for the treatments. For mammosphere formation assay,
cells (2.5 × 10^4 cells/well) were plated in 6-well low-
attachment plates after 24-h Dox treatment and then
evaluated for numbers of spheroids (mammospheres)
5 days later, in the absence of additional treatments,
as described previously (Montales et al. 2012). Cell
viability using cells plated at an initial density of 2 × 10^5
per well was measured by the trypan blue exclusion
method using the Vi-CELL cell viability analyzer
(Beckman Coulter Inc, Atlanta, GA, USA) (Montales
et al. 2015). The percent of apoptotic cells was evaluated
48-h after treatment by Annexin V staining (Trevisgen,
Gaithersburg, MD, USA), followed by analyses using a
Becton-Dickinson LSRFortessa Flow Cytometer (BD
Biosciences, San Jose, CA, USA) (Montales et al. 2015).
For all assays, treatment effects were determined from
three independent experiments in triplicate, with each
experiment representing a distinct T-MEC isolation.

Fluorescence-activated cell sorting (FACS)

Mammary tumors isolated from CDO and HFDO
before and after Dox treatments were evaluated for the
presence of basal stem cell-like, luminal progenitor and
tumor-initiating epithelial subpopulations as described
for Wnt1 Tg mice (Cho et al. 2008, Rahal et al. 2013b).
Tumors whose volumes did not change or decrease in
response to Dox were used for isolation of T-MECs after
Dox treatments. Briefly, freshly isolated T-MECs were
labeled with selected antibodies (Supplementary Table 2)
for 30 min on ice. Cells were washed in HBSS+ buffer
(Invitrogen), incubated with streptavidin-APC for 20 min
in ice, washed briefly with the same buffer and then
subjected to FACS on an LSRFortessa Flow Cytometer.
Dead cells were excluded using 4′,6-diamidino-2-
phenylindole (DAPI; 1 μg/mL; Sigma-Aldrich). For each
tumor sample (4–5 independent tumors for each diet
and/or treatment groups), the percentages of basal stem-
like (CD29^hi/CD24^+) luminal progenitor (CD29^hi/CD24^+)
and tumor-initiating (CD29^hi/CD24^+Thy1^+) cells within
the Lin^(-) epithelial population (Cho et al. 2008) were
analyzed using FACSDiva Software (BD Biosciences).

Tissue oxidative stress biomarker and plasma
metabolite levels

Mammary tissues and sera were obtained from PND85
WT CDO and HFDO (littermates of Wnt1 Tg CDO and
HFDO) generated as described in Fig. 1A (n = 6 mice/
group). The content of free aminothiols (reduced and
oxidized glutathione) in tissues were measured by
high-performance liquid chromatography and
coulometric electrochemical detection (HPLC-ED)
method utilizing CoulAssay System (Thermo Fisher
Scientific) and C18 (3.6 μm × 150 mm × 2.1 mm) reverse-
phase columns (Phenomenex Inc, Torrance, CA, USA)
as described previously (Melnyk et al. 1999). Plasma
levels of 2-hydroxyglutaric acid (2-OHG), tryptophan
(Trp) and kynurenine (Kyn) were measured by
following the published protocols (Gibson et al. 1993,
Medana et al. 2003), with slight modifications. Briefly,
100 μL plasma were mixed with an equal volume of
10% metaphosphoric acid and incubated on ice for
30 min. Supernatants were retrieved by centrifugation
(14,000 g for 15 min at 4°C), and aliquots (10–50 μL)
were subjected to LC–MS analysis using the Ultimate
3000 system from Dionex and LTQ XL Linear Ion
Trap Mass Spectrometer (Thermo Fisher Scientific)
and Kinetic C18 columns (2.6 μm × 50 mm × 2.1 mm)
(Phenomenex Inc) with a SecurityGuard ULTRA
Cartridge for analytical column protection. Samples
were eluted at 0.4 mL/min with acetonitrile/water
(50:50) mobile phase (pH 6.2) using an LC–MS
method with electrospray ionization in positive mode.
Metabolites were quantified by peak area comparisons
using commercially available standards.

In vitro assays of human breast cancer MCF7 cells

The human breast cancer cell line MCF7 was obtained
from the American Type Culture Collection (Manassas,
VA, USA) and authenticated by the company using
short-tandem repeat DNA profiling. Cells were used
between passage numbers 5 and 15. Cells were
propagated in Dulbecco’s modified Eagle medium
(Invitrogen) in 5% CO2:95% air at 37°C (Montales
et al. 2012) and were evaluated for apoptosis, viability
and ability to form mammosphere in response to Kyn
(10 μM) or 2-OHG (10 μM) (Sigma-Aldrich) in the
presence of Dox (100 nM). Treatments with Kyn and
2-OHG were carried out for 24 h under the culture
conditions described previously (Montales et al. 2012,
2014) in three independent experiments.
Data analyses
Data are presented as the mean±standard error of the mean (s.e.m.) and were compared by t-test or one-way ANOVA using the SigmaStat version 3.5 software (SPSS). A P value <0.05 was considered to be statistically significant.

Results
Maternal diet influenced mammary tumor formation in adult Wnt1 Tg offspring
We demonstrated previously that Wnt1 Tg offspring, exposed to HFD through their dams during gestation and lactation only, without further exposure after weaning, had increased tumor incidence and decreased tumor latency when evaluated at 6 months of age (Montales et al. 2014). We confirmed those findings in this study and used the same experimental paradigm to generate mice used in subsequent studies (Fig. 1A). Consistent with previous results, tumor incidence in HFDO at age ≤6 months was significantly greater than in CDO (Fig. 1B). HFDO also developed tumors at a significantly younger age than CDO (Fig. 1C). The higher tumor incidence and shorter tumor latency for HFDO were associated with higher body weights at weaning (PND21) and as adults, as HFDO (1 week after tumor detection) were ~1 month younger than CDO at sacrifice (Fig. 1C and D). Glucose levels were higher at weaning for HFDO than CDO (which could be due to the higher maltodextrin and sucrose content in maternal diet), but were comparable for the two groups at sacrifice (Fig. 1E).

Tumor volume response to Dox was comparable for adult CDO and HFDO offspring
Dox is a broad-spectrum anticancer drug used for many cancer types including breast cancer, but its application

Table 1  Comparison of left-ventricular function in mice with doxorubicin treatments.

<table>
<thead>
<tr>
<th>Heart function</th>
<th>CDO (n = 12)</th>
<th>HFDO (n = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-Dox</td>
<td>Post-Dox</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>469 ± 12</td>
<td>473 ± 31</td>
</tr>
<tr>
<td>Stroke volume (µL)</td>
<td>32.5 ± 1.3</td>
<td>33.0 ± 2.9</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>87.1 ± 3.5</td>
<td>79.3 ± 4.5</td>
</tr>
<tr>
<td>Cardiac output (mL/min)</td>
<td>15.3 ± 0.6</td>
<td>15.5 ± 1.5</td>
</tr>
</tbody>
</table>

*Doxorubicin cumulative dose = 16 mg/kg body weight; †CDO, control diet offspring; HFDO, high-fat diet offspring; values are mean ± s.e.m.

Figure 3  Gene expression in Dox-insensitive mammary tumors of CDO and HFDO. (A) Transcript levels were evaluated by QPCR and normalized to a factor from the geometric mean of expression of TATA-box-binding protein, β-actin and cyclophilin A, as described under “Materials and methods” section. Results (mean ± S.E.M.; n = 4 CDO and n = 6 HFDO individual tumors) are presented as fold change of gene expression. *P<0.05 for CDO vs HFDO. Representative sections immunostained for PTEN (B), EGR1 (C) and Ki-67 (D) are shown for CDO and HFDO tumors. The % of immunopositive cells for CDO and HFDO tumors (n = 4 individual tumors/group) were analyzed as described under ‘Materials and methods’ section. Values are reported as mean ± S.E.M. *P<0.05 for CDO vs HFDO; †P=0.08. Magnification = 20×; scale bar = 100 µm.
is limited by cardiotoxicity, dependent on accumulative dose, and the potential for development of drug resistance in patients (Rochette et al. 2015). To evaluate whether metabolic history may be a contributing factor to Dox responsiveness, we assessed Dox effects on tumors of CDO and HFDO, following the regimen shown in Fig. 2A. Mice of both diet groups, 1 week after initial tumor detection (by palpation), were intraperitoneally administered with Dox (8 mg/kg body weight) twice at 1-week interval and the study was terminated 1 week after the second Dox injection. Dox effects on cardiac parameters in CDO and HFDO before and after Dox treatments were compared to determine if the accumulative dose (16 mg/kg body weight) causes cardiotoxicity. The heart rate (HR) and stroke volume (SV) of left ventricle (LV) tended to be higher for HFDO than CDO before Dox treatment (pre-Dox), albeit these differences did not reach statistical significance (Table 1). Dox treatment nonsignificantly reduced both HR and SV from pre-Dox values in the HFDO, but had no effect in the CDO group (Table 1). Tumor volumes were evaluated for CDO and HFDO before and after Dox treatment; representative images for tumors that were insensitive to Dox treatments are shown in Fig. 2B and C. Of the 12 CDO mice with tumors, 7 responded to Dox with tumor volume reduction; the rest showed either increased (4/12) or no (1/12) tumor volume changes (Fig. 2D). For HFDO tumors, 6 of 12 had reduced tumor volumes with Dox, while the rest (6/12) showed increased tumor volumes (Fig. 2E). Thus, no differences in response to Dox regarding tumor volumes were noted between CDO and HFDO.

**Differences in gene expression of CDO and HFDO tumors**

Tumors from CDO and HFDO were further assessed for molecular markers of early pathologic response to Dox, given the comparable numbers of CDO (5 of 12) and HFDO (6 of 12) whose tumors did not decrease in volume with Dox treatment for 2 weeks (hence, Dox-insensitive). Expression of select tumor suppressor (Pten, Egr1), antiapoptotic (Bcl2), tumor inducer (Stat1, Il6) and stem cell marker (Notch1, Notch2, Aldh1) genes were evaluated by QPCR in Dox-insensitive HFDO and CDO tumors. Transcript levels for Pten, Egr1, Notch1 and Aldh1 were significantly elevated, while those for Notch2 were reduced in HFDO tumors, compared with those of CDO tumors (Fig. 3A). The levels of Bcl2, Il6 and Stat1 did not differ between the two groups. The higher Pten and Egr1 transcript levels in HFDO relative to CDO tumors were confirmed by their respective protein levels (Fig. 3B and C). HFDO tumors also showed higher
percentage of cells immunostaining for proliferative marker Ki-67 (Fig. 3D), but did not differ in apoptotic status (by TUNEL, data not shown), when compared with CDO tumors.

**Epithelial cell subpopulations in HFDO tumors are insensitive to Dox**

The histopathological and molecular subtypes of breast cancer are well acknowledged to arise from distinct epithelial lineages in the mammary glands (Prat & Perou 2011, Anderson et al. 2014). Mammary tumors in Wnt1 Tg mice were shown previously to contain basal stem cell-like, luminal progenitor and tumor-initiating cells, based on their distinct expression of specific cell-surface antigens CD29, CD24 and Thy1 (Cho et al. 2008). Subsequently, we also showed that the percentages of these subpopulations in pre-neoplastic mammary tissues of Wnt1 Tg mice were altered by dietary factors (Rahal et al. 2013b). To determine whether epithelial subpopulations from HFDO mammary tumors differ from those of CDO and further, whether Dox treatment alters the frequencies of these cell populations, the luminal progenitor, basal, and Thy1-positive epithelial cell subpopulation in non-Dox-treated and in Dox-insensitive CDO and HFDO mammary tumors were isolated (Fig. 4A) and their relative frequencies were quantified by FACS (Fig. 4B and C). In the absence of Dox, HFDO tumors showed higher % basal (CD29hiCD24+) epithelial subpopulation than CDO tumors (HFDO = 9.03 ± 3.62% vs CDO = 2.72 ± 0.84%, P < 0.05). Non-Dox CDO and HFDO tumors showed comparable % luminal (CD29loCD24+) and %Thy1+ (CD29hiCD24+Thy1+) epithelial subpopulations. Dox treatments decreased the frequencies of all three epithelial subpopulations in CDO tumors, but had no effect on those in HFDO tumors (Fig. 4B and C).

**Figure 5**

Systemic factors alter the response of epithelial mammary tumor cells to Dox. (A) Treatment strategy for mammary epithelial cells isolated from CDO and HFDO tumors to evaluate in vitro effects of added Dox and Sera. Sera were pooled in equal volumes from adult (postnatal day 85) WT CDO (n = 6) and WT HFDO (n = 6) littermates of Wnt1 Tg mice. Isolated epithelial mammary tumor cells were plated and treated with Dox with or without added sera. Treated cells were evaluated for mammosphere-forming activity (measured as percent of mammospheres formed per number of epithelial cells plated; % MFU). (B) Ability of epithelial mammary tumor cells grown in mammosphere plating medium with (+Dox) and without (−Dox) Dox treatment to form mammosphere. Results (mean ± s.e.m.) are from three independent experiments, with each experiment representing an individual tumor isolated from CDO and HFDO 1 week after the initial tumor detection. Values with different letter superscripts differed at P < 0.05. (C) Ability of Dox-treated epithelial mammary tumor cells (T-MEC) grown in mammosphere plating medium with CDO sera or HFDO sera added at 5% final concentration to form mammosphere. Sera were pooled from adult WT CDO (n = 6) and WT HFDO (n = 6) in equal volumes. Results (mean ± s.e.m.) are from three independent experiments, with each experiment representing individual tumors isolated from CDO and HFDO 1 week after initial tumor detection. Values with different letter subscripts differed at P < 0.05. (D and E) Human MCF7 breast cancer cells were treated with Dox + sera from either CDO or HFDO (added at 5% final concentration) and evaluated for % apoptotic cells (by annexin V-FACS) (D) and ability to form mammosphere (E). Results (mean ± s.e.m.) are from three independent experiments. For mammosphere formation assays (% MFU), each experiment was carried out in quadruplicate. *P < 0.05.
Systemic factors mediate Dox resistance of HFDO mammary tumors

We investigated if the lack of response to Dox of epithelial subpopulations present in HFDO tumors is mediated directly by systemic factors that were altered by early exposure to maternal HFD. We isolated mammary epithelial cells from CDO and HFDO tumors (designated T-MEC) 1 week after tumor detection and evaluated their response to Dox in vitro in the presence and absence of mouse sera harvested from PND85 WT CDO and PND85 WT HFDO. We reasoned that sera from the WT offspring more closely recapitulate systemic factors elicited by maternal HFD in the general population (i.e., without inborn genetic dysfunctions as in Wnt1 Tg mice). The schematic of the in vitro treatments is shown in Fig. 5A. Mammosphere formation is a well-accepted in vitro marker for stem cell activity (Dontu et al. 2003). Hence, the ratio of mammospheres formed with respect to the number of epithelial cells plated (×100; designated as % mammosphere-forming units, MFU) was used as a functional measure of the basal stem cell-like epithelial subpopulation. In the absence of Dox, HFDO T-MEC displayed higher % MFU than CDO T-MEC (Fig. 5B). Dox treatment reduced the % MFU in CDO T-MEC but not in HFDO T-MEC (Fig. 5B). Interestingly, mouse sera harvested from PND85 WT HFDO (HFDO sera) had higher ability than PND85 WT CDO sera (CDO sera) (both added at 5% final concentration) to induce mammosphere formation in CDO T-MEC in the presence of Dox (Fig. 5C). By contrast, HFDO sera and CDO sera elicited comparable ability to form mammosphere in Dox-treated HFDO T-MEC (Fig. 5C), suggesting that prior in vivo exposure to a HFD environment elicited maximal stem cell-like phenotype potential in mammary epithelial cells.

The human MCF7 cell line has been previously shown to display a basal stem-like subpopulation (Filmore & Kuperwasser 2008) similar to Wnt1 Tg mammary tumors. Dox-treated MCF7 cells showed significantly reduced apoptotic status (Fig. 5D) and enhanced mammosphere formation (Fig. 5E) with HFDO sera than with CDO sera (P<0.05).

Tumor-related metabolites differ in HFDO and CDO sera

Factors in HFDO sera that promoted stem cell-like activity in vitro (Fig. 5) may underlie the higher % basal stem cell-like subpopulation in HFDO relative to CDO tumors that showed Dox-insensitivity (Fig. 4B and C). To address this, we first evaluated whether mammary epithelial cells (MECs) isolated from mammary glands of WT CDO and WT HFDO display differences in stem cell-like activity as shown for T-MEC from CDO and HFDO (Fig. 5B). We found that WT MEC from HFDO had greater ability to form mammosphere than those from CDO (Fig. 6A). This is consistent with recent reports that human and murine tumor subtypes share features with FACS-purified normal cell types (Spike et al. 2012, Pfefferle et al. 2015). Moreover, similar to our previous findings (Montales et al. 2014), mammary glands from WT HFDO displayed greater oxidative stress status, as determined by elevated oxidized glutathione (GSSG) levels and lower ratio of reduced glutathione (GSH) to GSSG, than mammary glands from WT CDO (Fig. 6B). We subjected WT CDO and WT HFDO plasma to untargeted metabolomics LC–MS analyses and selected two candidate metabolites for further study, based on the differences in their plasma levels in WT CDO and WT HFDO and their reported linkages to cancer. 2-Hydroxyglutarate (2-OHG) is considered an...
oncometabolite and linked to breast cancer subtypes with poorer prognosis (Tang et al. 2014, Terunuma et al. 2014). We found higher plasma levels of 2-OHG in WT HFDO than in WT CDO (Fig. 6C). Increased tryptophan (Trp) catabolism to kynurenine (Kyn) has been suggested to have prognostic importance in cancers, due to the postulated role of Kyn in immune escape (Suzuki et al. 2010, Gostner et al. 2015). We found that plasma Kyn levels were also higher in WT HFDO relative to WT CDO, while there were no significant differences ($P=0.101$) in the levels of Trp between WT CDO (23.85 ± 2.61 μM) and WT HFDO (29.03 ± 8.92 μM). However, a higher plasma Kyn/Trp ratio for WT HFDO than WT CDO was observed (Fig. 6C).

To evaluate if elevated plasma Kyn and 2-OHG levels induced by early HFD exposure contribute to

**Figure 7**

*In vitro effects of kynurenine and 2-hydroxyglutarate in human breast cancer MCF7 cells.* (A) Treatment protocols for MCF7 cells with kynurenine (Kyn) or 2-hydroxyglutarate (2-OHG) in Dox-treated cells. Dox-treated cells with (+) and without (−) added Kyn (10 μM) were evaluated for apoptotic status (B), cell viability (C) and ability to form mammosphere (D). Results (mean ± s.e.m.) are from three independent experiments. For C and D, each experiment was conducted in quadruplicate. *$P<0.05$ between treatment groups. Dox-treated cells were similarly treated with 2-OHG (10 μM) and analyzed for apoptotic status (E), cell viability (F) and ability to form mammosphere (G), following the described protocols (A). Results (mean ± s.e.m.) are from three independent experiments. For F and G, each experiment was conducted in quadruplicate. *$P<0.05$ between treatment groups.
breast cancer cells’ response to Dox, we treated MCF7 cells with these metabolites in the presence of Dox and evaluated metabolite effects on apoptosis, cell viability and mammosphere formation (Fig. 7A). In Dox-treated treated cells, cotreatment with Kyn reduced apoptosis, had no effect on cell viability, and increased the ability to form mammosphere than without added Kyn (Fig. 7B, C and D). In contrast, 2-OHG cotreatment of Dox-treated cells (Fig. 7A) did not influence any of these parameters relative to Dox treatment alone (Fig. 7E, F and G).

**Discussion**

Increasing evidence supports the many adverse consequences of maternal obesity to the long-term health of progeny (Ruager-Martín et al. 2010, Houghton et al. 2016). Indeed, studies in mouse models have demonstrated causality between maternal obesity and offspring’s compromised cardiovascular health and increased cancer risks (Simmen & Simmen 2011, Blackmore et al. 2014). Consumption of a high-fat diet does not necessarily result in obesity. However, there is a growing consensus that maternal dietary intake of high fat mimicking a typical ‘Western diet’, similar to maternal obesity, elicits metabolic dysfunctions in progeny through early changes in metabolome due in part to deregulated insulin signaling (Cox et al. 2009, Montales et al. 2014, Vogt et al. 2014). Our studies described here for mouse Wnt1 Tg that recapitulates Wnt1-signaling dysfunctions in women with breast cancer (Deming et al. 2000, Lin et al. 2000) suggest that maternal dietary intake of high fat during pregnancy and lactation can negatively influence early tumor response to chemotherapy. We found that while tumor volume in response to short-term Dox treatment was not a sensitive indicator of effects of maternal metabolic stress, molecular markers associated with proliferation (Ki-67) and stemness (Notch1, Aldh1) can distinguish mammary tumors that originate from an environment with early metabolic perturbations. We show that maternal HFD exposure alters the frequencies of cell subpopulations along the epithelial hierarchy in mammary tumors of offspring, favoring expansion of the self-renewing, less-differentiated subpopulation with the ability to form mammosphere in vitro (Montales et al. 2012, dos Santos et al. 2013, Rahal et al. 2013b) and the ability to initiate tumors in vivo (Cho et al. 2008). Further, we report that Dox insensitivity of this tumor subpopulation in HFDO may be partly attributed to altered tryptophan metabolism leading to higher systemic levels of its catabolite kynurenine. Using the well-differentiated MCF7 human mammary breast cancer cell line, which is estrogen receptor-positive and displays a limited subpopulation of basal stem-like cells with tumor-initiating properties (Filmore & Kuperwasser 2008) similar to Wnt1-Tg mammary tumors, we show that serum-derived Kyn, but not 2-OHG, a metabolite also associated with poor breast cancer prognosis (Terunuma et al. 2014), can recapitulate the HFDO serum effects on reducing apoptosis and increasing mammosphere formation. Increased levels of Kyn relative to Trp have been recently reported to correlate with disease progression in lung cancer through its immunosuppressive effects (Suzuki et al. 2010) and to avert immune surveillance in several cancer types including breast cancer (Heng et al. 2015). Our collective results suggest a novel mechanism (altered Trp catabolism) and a specific target population (basal stem cell-like subpopulation), which are subject to maternal metabolic dysregulations that can influence early chemotherapeutic response of mammary tumors of progeny.

The contribution of the tryptophan catabolic pathway and its associated metabolites in bridging maternal metabolic status with breast cancer incidence and drug response in progeny is currently unknown. However, it is important to consider the contribution further, given that Kyn has been implicated in regulating stem cell biology (Jones et al. 2013) by virtue of its presumed role in inflammation, a known driver of stem cell expansion and dysregulation (Iliopoulos et al. 2011). Moreover, Kyn levels are highly elevated in the more aggressive estrogen receptor-negative relative to estrogen receptor-positive breast cancers (Tang et al. 2014). As tumors generated in Wnt1 Tg mice are reported to be refractory to both ovariectomy and the estrogen receptor antagonist tamoxifen (Zhang et al. 2005), we speculate that the higher levels of Kyn observed with early exposure to maternal high-fat diet may constitute early indicators of the evolution of estrogen-refractory tumors.

Our Dox treatment paradigm employed mice 1 week after initial tumor detection and a short-term Dox regimen of 2 weeks. The limited treatment duration and dose were adopted to eliminate confounding effects of cardiac dysfunctions that may arise in tumor-bearing mice with prolonged Dox treatment. The higher heart rate and stroke volume in HFDO than in those of CDO before Dox treatment concur with HFD promotion of metabolic stress. Although we did not expect the 16 mg/kg cumulative dose of Dox to significantly elicit cardiac pathology, Dox treatment decreased heart rates and stroke volumes, resulting in the lower cardiac output of HFDO. These effects are anticipated to be more apparent (and hence, significant) with chronic Dox treatment.
Interestingly, while individual tumor volume responses to Dox were comparable between CDO and HFDO, the more sensitive parameters of gene expression, epithelial subpopulation frequencies and self-renewal capacity provided support for the significantly reduced Dox responsiveness of HFDO than CDO tumors. Future studies will address whether, with protracted Dox treatments, tumor volume response and the molecular parameters evaluated here will be more stringently correlated to conclusively establish a causal relationship between early-life exposure to maternal dysfunction and tumor drug resistance.

The higher levels of EGR1 transcription factor in HFDO compared with CDO tumors, while counter to its previously reported tumor-suppressing function (Huang et al. 1997), are consistent with its recently reported role as an oncogene (Li et al. 2013) and in enhancing drug resistance of breast cancer cells (Tao et al. 2013). Moreover, the lack of Dox treatment effects on the frequencies of basal (CD29hiCD24+), luminal (CD29loCD24+) and tumor-initiating (CD29loCD24+Thy1+) epithelial subpopulations in HFDO and the higher transcript levels of stem cell markers Notch 1 and Aldh1 in HFDO than in CDO tumors are congruent with the reported positive association between drug insensitivity and expansion of breast cancer stem cells. Notably, the increased resistance to tamoxifen, an antiestrogen receptor-positive breast cancer drug, was accompanied by the selection of breast cancer cells with the ability to form mammosphere (Raffo et al. 2013). Further, in mouse xenograft models of breast cancer, the tyrosine kinase inhibitor sunitinib was found to reduce the ability of maternal metabolic status to potentially influence breast cancer risk and treatment in progeny may uncover insights underlying the heterogeneity of response to chemotherapeutic drugs of women with breast cancer.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-16-0136.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by the Arkansas Breast Cancer Research Program, the University of Arkansas for Medical Sciences Translational Research Institute (CTSA Grant Award UL1TR000039) and the National Institutes of Health/National Cancer Institute (R01CA136493).

Author’s contribution statement
R C M Simmen and F A Simmen were involved in the conception and design. M T E Montales, S B Melnyk, S J Liu and Y L Liu were involved in the acquisition of data. M T E Montales, S B Melnyk, S J Liu, Y L Liu, F A Simmen and R C M Simmen were involved in the analyses and interpretation of data. M T E Montales, S B Melnyk, S J Liu, Y L Liu, F A Simmen and R C M Simmen were involved in writing, review and/or revision of this manuscript.

Acknowledgements
The authors thank Olekssandra Pavliv and Mahdad Shroff for technical assistance and Andrea Harris (UAMS Flow Core) for assistance with flow cytometry analyses.
References


Metabolic history and mammary tumor early drug response


Received in final form 21 June 2016
Accepted 8 July 2016
Accepted Preprint published online 8 July 2016